MARKET

SNDX

SNDX

Syndax Pharmaceuticals Inc
NASDAQ
9.59
-0.23
-2.34%
After Hours: 9.59 0 0.00% 17:43 07/11 EDT
OPEN
9.74
PREV CLOSE
9.82
HIGH
9.82
LOW
9.48
VOLUME
1.51M
TURNOVER
--
52 WEEK HIGH
25.07
52 WEEK LOW
8.58
MARKET CAP
825.20M
P/E (TTM)
-2.4875
1D
5D
1M
3M
1Y
5Y
1D
SNDX, NUVB, AURA : 3 Russell 2000 Stocks Analysts Say Could Soar Over 200%
TipRanks · 15h ago
Syndax Pharmaceuticals’ Axatilimab Study: A Potential Breakthrough for IPF Treatment
TipRanks · 1d ago
Syndax Pharmaceuticals Price Target Announced at $18.00/Share by Goldman Sachs
Dow Jones · 1d ago
Goldman Sachs Initiates Coverage On Syndax Pharmaceuticals with Buy Rating, Announces Price Target of $18
Benzinga · 1d ago
Syndax initiated with a Buy at Goldman Sachs
TipRanks · 1d ago
Promising Growth Potential for Syndax Pharmaceuticals Driven by Revuforj and Strategic Partnerships
TipRanks · 1d ago
Syndax Pharmaceuticals: Oversold Pharma Likely To Benefit From Drug Approvals
Seeking Alpha · 3d ago
Weekly Report: what happened at SNDX last week (0630-0704)?
Weekly Report · 4d ago
More
About SNDX
Syndax Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. It is focused on developing a pipeline of cancer therapies. Its product candidates include Revuforj and Niktimvo. It is developing Revuforj, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant AML. It is also exploring the use of Revuforj as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. It is also developing Niktimvo, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells.

Webull offers Syndax Pharmaceuticals Inc stock information, including NASDAQ: SNDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SNDX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SNDX stock methods without spending real money on the virtual paper trading platform.